A team of scientists is now applying the power of artificial intelligence (AI) and high-performance supercomputers to accelerate efforts to analyze the increasingly massive datasets produced by ongoing and future cosmological surveys. In a new study, researchers from NCSA and Argonne have developed a novel combination of deep learning methods to provide a highly accurate approach to classifying hundreds of millions of unlabeled galaxies. The team's findings were published in Physics Letters B. "The NCSA Gravity Group initiated, and continues to spearhead, the use of deep learning at scale for gravitational wave astrophysics. We have expanded our research portfolio to address a computational grand challenge in cosmology, innovating the use of several deep learning methods in combination with high-performance computing (HPC)," said Eliu Huerta, NCSA Gravity Group Lead. "Our work also showcases how the interoperability of NSF and DOE supercomputing resources can be used to accelerate science."

One of the hot trends in artificial intelligence (AI) revolves around the use of deep learning (DL) technologies for image and video classification. These AI-driven applications use computer vision to classify or categorize an image or video file on the basis on its visual content. So, what is deep learning? In a few words, DL is a subset of machine learning (ML), and one of the key building blocks for AI solutions. It uses artificial neural networks as the underlying architecture for training algorithms, or models.

What would an adventure game designed by the worlds most dangerous A.I. look like? A neuroscience grad student is here to help you find out. Earlier this year, OpenAI, an A.I. startup once sponsored by Elon Musk, created a text-generating bot deemed too dangerous to ever release to the public. Called GPT-2, the algorithm was designed to generate text so humanlike that it could convincingly pass itself off as being written by a person. Feed it the start of a newspaper article, for instance, and it would dream up the rest, complete with imagined quotes.

Energy-Based Models(EBM) is one of the most promising areas of deep learning that hasn't seen a tremendous level of adoption yet. Conceptually, EBMs are a form of generative modeling that learns the key characteristics of a target dataset and tries to generate similar datasets. While EBMs results appealing because of its simplicity they have experienced many challenges when applied in real world applications. Recently, AI-powerhouse OpenAI published a new research paper that explores a new technique to create EBM model that can scale across complex deep learning topologies. EBMs are typically used in one of the most complex problems of real world deep learning solutions: generating quality training datasets.

Biotechnology, pharmaceutical, and life sciences industries are where applied artificial intelligence (AI) can greatly accelerate innovation and shorten the product development life-cycle. Developing a drug typically takes 10 to 15 years on average, with only approximately 12 percent of drugs in clinical trials ultimately gaining U.S. Food and Drug Administration (FDA) approval. In an AI milestone in life sciences, Insilico Medicine announced a new machine learning tool for drug discovery that can generate a novel molecule in days instead of years and published their findings in Nature Biotechnology on September 2, 2019. Insilico Medicine is a venture-backed start-up with multiple investors that include WuXi AppTec, Juvenescence, Peter Diamandis' BOLD Capital Partners, and Pavilion Capital. Led by CEO and Founder Alex Zhavoronkov, the company's mission is to extend longevity by applied AI solutions for drug discovery and aging research.

Biotechnology, pharmaceutical, and life sciences industries are where applied artificial intelligence (AI) can greatly accelerate innovation and shorten the product development life-cycle. Developing a drug typically takes 10 to 15 years on average, with only approximately 12 percent of drugs in clinical trials ultimately gaining U.S. Food and Drug Administration (FDA) approval. In an AI milestone in life sciences, Insilico Medicine announced a new machine learning tool for drug discovery that can generate a novel molecule in days instead of years and published their findings in Nature Biotechnology on September 2, 2019. Insilico Medicine is a venture-backed start-up with multiple investors that include WuXi AppTec, Juvenescence, Peter Diamandis' BOLD Capital Partners, and Pavilion Capital. Led by CEO and Founder Alex Zhavoronkov, the company's mission is to extend longevity by applied AI solutions for drug discovery and aging research.

These Docker images use popular frameworks and are performance optimized, compatibility tested, and ready to deploy. Deep Learning Containers provide a consistent environment across Google Cloud services, making it easy to scale in the cloud or shift from on-premises. You have the flexibility to deploy on Google Kubernetes Engine (GKE), AI Platform, Cloud Run, Compute Engine, Kubernetes, and Docker Swarm.

So I've built a (relatively) simple web app with a deep learning image classifier, and I have it running on localhost. How do I upload this to the web so that I can link to it from my website? The usage will not be very high at all, but the model needs GPU so it would be better if it's a pay/hour used or something similar. What are the best services to use to do this (as cheap as possible)?

These research-based efforts were seen earlier last week, as a brand new'artificial intelligence powered X-ray device' that GE Healthcare claimed could reduce the time interval in detecting a collapsed lung by a staggering factor of 32, from 8 hours to 15 minutes, was cleared by the Food and Drug Administration (FDA). GE Healthcare CEO Kieran Murphy, in an interview with CNBC, said, "The health-care industry is producing huge amounts of data from images to digital health records, we strongly believe that you have to turn that data into information and insight to improve outcomes." The device, coined the'Critical Care Suite', utilizes artificial intelligence-based algorithms to scan X-ray images and detect cases of collapsed lung. One can only assume that deep learning algorithms are put in use to identify trends and patterns in the data sets that Kieran Murphy mentions, and is assessed in its efficacy to spot recurrent themes in a new sample of data. When the AI system has reason to suspect any condition, the scan is sent off to a radiologist as a confirming measure, and as such this is another example of AI-assisted healthcare, not AI-led, as is the reasonable role of artificial intelligence given its youth in the healthcare industry.

DeepMind also had its mobile assistant for clinicians, known as Streams, evaluated by researchers at University College London. The results show that, through the app, specialists reviewed urgent cases within 15 minutes, as opposed to several hours. And only 3.3 percent of AKI cases were missed, compared to 12.4 percent without the app. Streams also led to health care cost savings. Combined with DeepMind's new AKI-detecting algorithm, Streams could offer improved early detection.